More recently, a global population‐based retrospective cohort study reported that psoriasis patients treated with interleukin (IL)‐17 inhibitors (IL‐17i) or IL‐23 inhibitors (IL‐23i) had a lower risk of several malignancies compared with those treated with TNFi [15]. This evidence concerns the gene IL23A and psoriasis.